These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34102605)

  • 1. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.
    Sedaghat N
    Mult Scler Relat Disord; 2021 Aug; 53():103054. PubMed ID: 34102605
    [No Abstract]   [Full Text] [Related]  

  • 2. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.
    Barzegar M; Vaheb S; Mirmosayyeb O; Afshari-Safavi A; Nehzat N; Shaygannejad V
    Mult Scler Relat Disord; 2021 Jul; 52():102947. PubMed ID: 33979771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series.
    Chisari CG; Toscano S; Arena S; Finocchiaro C; Montineri A; Patti F
    BMC Neurol; 2021 Nov; 21(1):462. PubMed ID: 34839814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
    Preziosa P; Rocca MA; Nozzolillo A; Moiola L; Filippi M
    J Neurol; 2021 Aug; 268(8):2697-2699. PubMed ID: 33216223
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
    Mantero V; Baroncini D; Balgera R; Guaschino C; Basilico P; Annovazzi P; Zaffaroni M; Salmaggi A; Cordano C
    J Neurol; 2021 Jun; 268(6):2029-2030. PubMed ID: 32865629
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
    Luetic G; Menichini ML; Burgos M; Alonso R; Carnero Contentti E; Carrá A; Deri N; Steinberg J; Rojas JI;
    Mult Scler Relat Disord; 2021 Aug; 53():103049. PubMed ID: 34130197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
    Etemadifar M; Sedaghat N; Aghababaee A; Kargaran PK; Maracy MR; Ganjalikhani-Hakemi M; Rayani M; Abhari AP; Khorvash R; Salari M; Nouri H
    Mult Scler Relat Disord; 2021 Jun; 51():102915. PubMed ID: 33799284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis.
    Habek M
    Neurol Sci; 2021 Oct; 42(10):4003-4005. PubMed ID: 34331616
    [No Abstract]   [Full Text] [Related]  

  • 10. Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak.
    Stojanov A; Malobabic M; Milosevic V; Stojanov J; Vojinovic S; Stanojevic G; Stevic M
    Mult Scler Relat Disord; 2020 Oct; 45():102407. PubMed ID: 32702641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis following SARS-CoV-2 infection.
    Palao M; Fernández-Díaz E; Gracia-Gil J; Romero-Sánchez CM; Díaz-Maroto I; Segura T
    Mult Scler Relat Disord; 2020 Oct; 45():102377. PubMed ID: 32698095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis and COVID-19.
    Mares J; Hartung HP
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):217-225. PubMed ID: 32686774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
    Guevara C; Villa E; Rosas CS; Diaz V; Naves R
    Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
    [No Abstract]   [Full Text] [Related]  

  • 14. Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis.
    Devogelaere J; D'hooghe MB; Vanderhauwaert F; D'haeseleer M
    Neurol Sci; 2020 Aug; 41(8):1981-1983. PubMed ID: 32564270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
    Fernández-Díaz E; Gracia-Gil J; García-García JG; Palao M; Romero-Sánchez CM; Segura T
    Mult Scler Relat Disord; 2020 Oct; 45():102402. PubMed ID: 32711297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
    Chiarini M; Paghera S; Moratto D; Rossi N; Giacomelli M; Badolato R; Capra R; Imberti L
    J Neuroimmunol; 2020 Aug; 345():577282. PubMed ID: 32505908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
    Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
    Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
    [No Abstract]   [Full Text] [Related]  

  • 18. One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients.
    Naser Moghadasi A
    Mult Scler Relat Disord; 2020 Jun; 41():102138. PubMed ID: 32335508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
    De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
    Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
    Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.